Skip to main content
PRGO
NYSE Life Sciences

Perrigo Finalizes Interim CEO Compensation with $2.5M RSU Grant

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.09
Mkt Cap
$1.534B
52W Low
$9.225
52W High
$28.435
52W Position info
20% above low
Off High info
61% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PRGO sits 20% above its 52-week low of $9.225.

Summary

Perrigo has disclosed the compensation package for its Interim President and CEO, Albert A. Manzone, including a $1.27 million annual salary and a $2.5 million restricted stock unit grant.


Key Events · Executive and Board Changes · PRGO

  • Interim CEO Compensation Finalized

    Perrigo has disclosed the definitive compensatory arrangements for Albert A. Manzone, who was appointed Interim President and Chief Executive Officer on June 7, 2026.

  • Substantial Equity Grant Awarded

    Mr. Manzone will receive a one-time special restricted stock unit (RSU) grant with a grant-date fair value of $2.5 million, vesting upon the earlier of one year, the hiring of a permanent CEO, or a change of control.

  • Fixed Term and Base Salary

    The interim employment agreement is for a fixed term from June 7, 2026, to December 31, 2026, with an annual base salary of $1.27 million.

  • Performance-Based Cash Bonus

    A one-time cash bonus of $250,000 is included, subject to performance metrics approved by the board of directors.


Analysis · PRGO · Life Sciences

This amendment provides the full compensation details for Albert A. Manzone, who was appointed Interim President and CEO following the previous CEO's resignation. The package includes a $1.27 million annual base salary, a $250,000 performance bonus, and a significant $2.5 million restricted stock unit grant. These terms are important for understanding the company's leadership costs during a period of transition and financial challenges, especially after a recent CEO departure due to personal conduct and a substantial Q1 net loss.

At the time of this filing, PRGO was trading at $11.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRGO - Latest Insights

PRGO
Aug 05, 2026, 1:44 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.28
Real-time Price: $12.84 info
Change: -$0.440 (-3%) info
Market Cap: $1.782B info
PRGO
Aug 05, 2026, 6:37 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.99
Real-time Price: $12.84 info
Change: +$1.85 (+17%) info
Market Cap: $1.782B info
PRGO
Jun 30, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.39
Real-time Price: $12.84 info
Change: +$2.45 (+24%) info
Market Cap: $1.782B info
PRGO
Jun 08, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.51
Real-time Price: $12.84 info
Change: +$1.33 (+12%) info
Market Cap: $1.782B info
PRGO
Jun 08, 2026, 4:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $11.51
Real-time Price: $12.84 info
Change: +$1.33 (+12%) info
Market Cap: $1.782B info